Novita Healthcare (ASX:NHL) has reaped more rewards of its US push, signing a deal to access a school district containing more than 14,000 students.
It told its investors today that it had signed on with the Nampa school district in Idaho — with children in the district to use the company’s Tali Train product.
Tali will initially be used by 50 kids in the district, which will give the company a good base for further sales in the US.
Nampa has three special education programs — the types of programs the company thinks would be a great delivery channel for its product to a potential market of 5 million kids with a target clinical diagnosis.
“Working with credible and forward-thinking schools is a primary goal of Novita to ensure the widespread adoption of Tali in the USA,” managing director Glenn Smith said.
“We welcome the commencement of Tali in Idaho as part of our wider USA deployment activities.”
The company has identified the US as a key market for Tali after its solution was listed by the FDA last year.
It’s also further evidence that a recent trip to the US to present at the Global Digital Therapeutics Conference has seemingly paid off for the company — with the Idaho deal to provide great in-market data for a further sales push.
It has already secured a partnership with CareStarter in the US — giving it a channel which contains 25,000 families.
CareStarter is venture-backed platform which automates and scales paediatric care management, and is able to deliver STAR Kids plans in Texas.
With market entrances in both Idaho and Texas through the school system and private care system respectively, Novita will now have in-market data it can use to present to secure further sales deals in the US.
About Novita and Tali
Novita’s flagship technology is the Tali Train product, which is a brain training game designed to improve attention in inattentive children — usually from the ages of three to eight.
It’s backed by more than a decade of research, and is usually delivered over five weeks on a SaaS model.
It’s the result of research originating from Monash University in Melbourne, and is available as part of the NDIS program in Australia.
While Novita has built its base in Australia it has also had its eyes on international expansion — with the US identified as a key market, although it has also done some early sales work in Asia.
It is also expected to deliver Tali Detect, a program to help identify severe inattention issues in young children before it becomes a problem in the classroom, by the end of the year — giving it a foot in both identifying inattention issues and treating them without the use of psychostimulant drugs such as Ritalin.